Article
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Cancer research - 15 Nov 2008
Eichhorn Pieter J A, Gili Magüi, Scaltriti Maurizio, Serra Violeta, Guzman Marta, Nijkamp Wouter, Beijersbergen Roderick L, Valero Vanesa, Seoane Joan, Bernards René, Baselga José
Abstract excerpt
Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.